Definition of Stereotactic Body Radiotherapy: Principles and Practice for the Treatment of Stage I Non-small Cell Lung Cancer

Overview

Journal Strahlenther Onkol

Specialties Oncology
Radiology

Date 2013 Sep 21

PMID 24052011

Citations 107

Authors

M Guckenberger

N Andratschke

H Alheit

R Holy

C Moustakis

U Nestle

O Sauer

Affiliations

Soon will be listed here.

Abstract

This report from the Stereotactic Radiotherapy Working Group of the German Society of Radiation Oncology (Deutschen Gesellschaft für Radioonkologie, DEGRO) provides a definition of stereotactic body radiotherapy (SBRT) that agrees with that of other international societies. SBRT is defined as a method of external beam radiotherapy (EBRT) that accurately delivers a high irradiation dose to an extracranial target in one or few treatment fractions. Detailed recommendations concerning the principles and practice of SBRT for early stage non-small cell lung cancer (NSCLC) are given. These cover the entire treatment process; from patient selection, staging, treatment planning and delivery to follow-up. SBRT was identified as the method of choice when compared to best supportive care (BSC), conventionally fractionated radiotherapy and radiofrequency ablation. Based on current evidence, SBRT appears to be on a par with sublobar resection and is an effective treatment option in operable patients who refuse lobectomy.

Citing Articles

The Role of Stereotactic Body Radiotherapy in Oligometastatic Non-Small Cell Lung Cancer.

Wan B, Lecavalier-Barsoum M Curr Oncol. 2024; 31(12):7971-7978.

PMID: 39727711 PMC: 11674643. DOI: 10.3390/curroncol31120588.

Treating early-stage centrally-located non-small cell lung cancer with DCAT-SBRT in centers lacking the VMAT technique: a comprehensive study.

Huang Y, Yang J, Song R, Qin T, Yang M, Liu Y Front Oncol. 2024; 14:1431082.

PMID: 39703844 PMC: 11655335. DOI: 10.3389/fonc.2024.1431082.

Radiomics As Biomarkers for the Treatment of Non-small Cell Lung Cancer With Stereotactic Body Radiation Therapy: A Review of Concepts.

Ramasamy G, Muanza T Cureus. 2024; 16(11):e73082.

PMID: 39640122 PMC: 11620770. DOI: 10.7759/cureus.73082.

The role of ALBI score in patients treated with stereotactic body radiotherapy for locally advanced primary liver tumors: a pooled analysis of two prospective studies.

Gkika E, Radicioni G, Eichhorst A, Kirste S, Sprave T, Nicolay N Front Oncol. 2024; 14:1427332.

PMID: 39421444 PMC: 11484445. DOI: 10.3389/fonc.2024.1427332.

Stereotactic Body Radiotherapy for Renal Cell Carcinoma-A Review of Use in the Primary, Cytoreductive and Oligometastatic Settings.

Villafuerte C, Swaminath A Cancers (Basel). 2024; 16(19).

PMID: 39409955 PMC: 11475850. DOI: 10.3390/cancers16193334.

References

Stiles B, Servais E, Lee P, Port J, Paul S, Altorki N . Point: Clinical stage IA non-small cell lung cancer determined by computed tomography and positron emission tomography is frequently not pathologic IA non-small cell lung cancer: the problem of understaging. J Thorac Cardiovasc Surg. 2009; 137(1):13-9. DOI: 10.1016/j.jtcvs.2008.09.045. View

Fuks Z, Kolesnick R . Engaging the vascular component of the tumor response. Cancer Cell. 2005; 8(2):89-91. DOI: 10.1016/j.ccr.2005.07.014. View

Haasbeek C, Palma D, Visser O, Lagerwaard F, Slotman B, Senan S . Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands. Ann Oncol. 2012; 23(10):2743-2747. DOI: 10.1093/annonc/mds081. View

Oshiro Y, Aruga T, Tsuboi K, Marino K, Hara R, Sanayama Y . Stereotactic body radiotherapy for lung tumors at the pulmonary hilum. Strahlenther Onkol. 2010; 186(5):274-9. DOI: 10.1007/s00066-010-2072-y. View

Bolliger C, Wyser C, ROSER H, Soler M, Perruchoud A . Lung scanning and exercise testing for the prediction of postoperative performance in lung resection candidates at increased risk for complications. Chest. 1995; 108(2):341-8. DOI: 10.1378/chest.108.2.341. View

Lax I, Blomgren H, Naslund I, Svanstrom R . Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol. 1994; 33(6):677-83. DOI: 10.3109/02841869409121782. View

Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J . Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010; 303(11):1070-6. PMC: 2907644. DOI: 10.1001/jama.2010.261. View

Haasbeek C, Lagerwaard F, Slotman B, Senan S . Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol. 2011; 6(12):2036-43. DOI: 10.1097/JTO.0b013e31822e71d8. View

Huang K, Dahele M, Senan S, Guckenberger M, Rodrigues G, Ward A . Radiographic changes after lung stereotactic ablative radiotherapy (SABR)--can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiother Oncol. 2012; 102(3):335-42. DOI: 10.1016/j.radonc.2011.12.018. View

10.

Takeda T, Takeda A, Kunieda E, Ishizaka A, Takemasa K, Shimada K . Radiation injury after hypofractionated stereotactic radiotherapy for peripheral small lung tumors: serial changes on CT. AJR Am J Roentgenol. 2004; 182(5):1123-8. DOI: 10.2214/ajr.182.5.1821123. View

11.

Sahgal A, Roberge D, Schellenberg D, Purdie T, Swaminath A, Pantarotto J . The Canadian Association of Radiation Oncology scope of practice guidelines for lung, liver and spine stereotactic body radiotherapy. Clin Oncol (R Coll Radiol). 2012; 24(9):629-39. DOI: 10.1016/j.clon.2012.04.006. View

12.

Kirkbride P, Cooper T . Stereotactic body radiotherapy. Guidelines for commissioners, providers and clinicians: a national report. Clin Oncol (R Coll Radiol). 2011; 23(3):163-4. DOI: 10.1016/j.clon.2011.01.155. View

13.

Paddick I . A simple scoring ratio to index the conformity of radiosurgical treatment plans. Technical note. J Neurosurg. 2001; 93 Suppl 3:219-22. DOI: 10.3171/jns.2000.93.supplement. View

14.

Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K . Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004; 101(7):1623-31. DOI: 10.1002/cncr.20539. View

15.

Senthi S, Haasbeek C, Slotman B, Senan S . Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. Radiother Oncol. 2013; 106(3):276-82. DOI: 10.1016/j.radonc.2013.01.004. View

16.

Rowell N, Williams C . Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable). Cochrane Database Syst Rev. 2001; (1):CD002935. DOI: 10.1002/14651858.CD002935. View

17.

Wulf J, Baier K, Mueller G, Flentje M . Dose-response in stereotactic irradiation of lung tumors. Radiother Oncol. 2005; 77(1):83-7. DOI: 10.1016/j.radonc.2005.09.003. View

18.

Murai T, Shibamoto Y, Baba F, Hashizume C, Mori Y, Ayakawa S . Progression of non-small-cell lung cancer during the interval before stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2010; 82(1):463-7. DOI: 10.1016/j.ijrobp.2010.10.001. View

19.

Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, Deluca J . Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006; 24(30):4833-9. DOI: 10.1200/JCO.2006.07.5937. View

20.

Guckenberger M, Heilman K, Wulf J, Mueller G, Beckmann G, Flentje M . Pulmonary injury and tumor response after stereotactic body radiotherapy (SBRT): results of a serial follow-up CT study. Radiother Oncol. 2007; 85(3):435-42. DOI: 10.1016/j.radonc.2007.10.044. View